Clariant Healthcare unveiled its latest portfolio of products tailored for the pharmaceutical industry at CPHI India, emphasizing its “Made in India” offerings, cutting-edge Bonthapally operations, and expertise in biologics, generics, and excipients. These innovations aim to meet the evolving demands of India’s growing healthcare sector with high-quality, cost-effective, and customized solutions.
“Our Made in India products play a critical role in enhancing drug formulation, delivery, and patient outcomes while maintaining compliance with the highest industry standards,” said Vaios Barlas, Global Head of Healthcare at Clariant.
Expanding India’s Role in Global Healthcare Manufacturing
India’s prominence in global pharmaceutical manufacturing is underscored by supplying over 50% of global vaccines and 40% of generic drugs. Clariant leverages this capacity by integrating Swiss expertise with Indian manufacturing capabilities to ensure a consistent supply of ultra-pure excipients. These are vital for the stability, bioavailability, and efficacy of active pharmaceutical ingredients (APIs).
“Our Bonthapally facility caters to specialized regional needs while meeting stringent global standards, making Clariant a preferred partner in biologics, injectables, and complex drug formulations,” said Bhushan Thekedar, Head of Global Business Development, Healthcare at Clariant.
Innovations in Excipients
Clariant highlighted several product launches designed to address challenges in API delivery, bioavailability, and stability:
- VitiPure LEX Product Line
VitiPure LEX 3350 S and VitiPure LEX 4000 S: Optimized for sensitive applications with low endotoxin levels, these co-solvents surpass pharmacopoeia requirements for parenteral applications.
Polyglykol 1450 S: A polyethylene glycol co-solvent adhering to USP-NF monograph standards, offering ease of handling and exceeding international pharmacopoeia benchmarks.
2. VitiPure Superior Line
VitiPure CO 35 Superior, VitiPure O 80 Superior, and VitiPure L 20 Superior: These nearly colorless excipients reduce impurities, ensuring stability and safety for parenteral applications and sensitive APIs.
3. VitiPure Meglumine LEX
Designed for low bioburden and low endotoxin formulations, Meglumine LEX serves as a solubilizer, buffering agent, and bioavailability enhancer, suitable for parenteral use.
4. VitiPure HCO
A hydrogenated castor oil developed for tablet formulations as a lubricant or sustained-release agent, also effective as a consistency factor in topical applications.
Commitment to Excellence
Clariant’s Bonthapally facility is equipped with advanced cleanroom environments to ensure sterility and purity, supporting global healthcare needs. By adhering to FDA, EMA, and other regulatory standards, Clariant positions itself as a leader in innovative excipient solutions.
As reported by expresspharma, through these advancements, Clariant reinforces its commitment to supporting the pharmaceutical sector with reliable, high-purity products that contribute to improved patient outcomes and global healthcare progress.